Please ensure Javascript is enabled for purposes of website accessibility

Wuhan Coronavirus Hits the U.S. And Vaccine Stock Soars

By Taylor Carmichael - Updated Jan 21, 2020 at 4:10PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Vaccine-maker Novavax is running up on the news the coronavirus has infected a person in Washington state.

A mysterious new virus in China has infected more than 300 people and killed six. According to the Centers for Disease Control and Prevention (CDC), this coronavirus started in Wuhan City in China's Hubei Province and has spread to Thailand, Japan, and South Korea. On Tuesday, the CDC confirmed the virus reached the U.S., with a man in Washington state falling ill.  

Shares of certain biotech stocks are soaring in response. Novavax (NVAX 15.12%) is up 73% today from its closing price Friday. The vaccine specialist has its lead compound, NanoFlu, in phase 3 trials to help stop the recent flu outbreak that has resulted in 57,000 deaths. But the company's platform, vaccines based on recombinant nanoparticle technology, has also been used against the MERS (Middle East Respiratory Syndrome) coronavirus and the SARS (Severe Acute Respiratory Syndrome) coronavirus. 

face masks in China

Image source; Getty Images

Developing a new type of vaccine

Novavax has reported success in animal models against both SARS and MERS. One big problem with using vaccines against emerging pathogens is that the drugs need to be approved by regulatory bodies, a process that can take years. SARS, a coronavirus that made headlines in 2003, infected more than 8,000 people and killed 775 people. MERS, identified in 2012, infected 345 people and killed 107 of them. These diseases are scary because a significant percentage of people who get the virus die. 

The flu kills many more people, which is part of why Novavax has done human trials for its flu vaccine but not for its drugs for SARS or MERS. While those viruses are highly dangerous, they are also limited in scope. Still, today's run-up is a vote of confidence that Novavax could find a vaccine if this new pathogen becomes widespread.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$59.99 (15.12%) $7.88

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
328%
 
S&P 500 Returns
116%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.